EVOO and Metabolic Liver Health in MASLD

Summary

MASLD is currently one of the most common chronic non-communicable diseases and the leading cause of liver-related mortality and morbidity, with a rising prevalence worldwide, especially in the presence of obesity, diabetes, and other cardio-metabolic risk factors. Lifestyle modification, particularly through the Mediterranean Diet, is the first-line intervention, and extra virgin olive oil is a key component thanks to its monounsaturated fatty acids and bioactive compounds with anti-inflammatory and antioxidant effects. Several studies indicate that extra virgin olive oil supplementation, especially within a Mediterranean Diet pattern, reduces hepatic steatosis, improves inflammation, oxidative stress, and glucose and lipid profiles, and may promote weight loss and reduction of fat mass, also through potential effects on the gut microbiota. EFSA recognizes protective effects with a daily intake of at least 20 g of extra virgin olive oil, but it is still unclear whether this amount is optimal for individuals with MASLD, particularly those who are overweight or obese

Eligibility

Inclusion Criteria:

* Subjects with 20 ≤ BMI \< 30;
* Age range between 18 and 65 years, both sexes;
* Diagnosis of hepatic steatosis, made on the basis of recognized criteria (FibroScan \[CAP (controlled attenuation parameter) \> 288 dB/m\], FLI).

Exclusion Criteria:

* Subjects with BMI \< 20 and BMI \> 30.
* Presence of any condition that may influence the occurrence of steatosis other than the conditions representing inclusion criteria.
* Pregnancy or breastfeeding.
* Severe medical conditions that may compromise participation in the trial.
* Individuals following a special diet.

Conditions3

Browse More Trials